drugset / Trial / NCT05515562
Effects of Intravenous (IV) Omadacycline on Gut Microbiome
Phase 4
Completed
8 enrolled
Wake Forest University Health Sciences
High Point University · collabParatek Pharmaceuticals Inc · collabUniversity of Houston · collab
NaSingle-groupOpen-labelTreatment
Summary
Given the clinical need to improve upon current antibiotic regimens for the treatment of C. difficile infection with a particular focus on the impact of therapies on gut microbiome, this study proposes to characterize the impact of Intravenous (IV) omadacycline on gut microbiome of healthy volunteers.
Timeline
- Start
- 2023-03-20
- Primary completion
- 2023-07-11
- Completion
- 2023-07-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omadacycline | Small molecule | — | Intravenous |
Indications
No indication recorded.